CCP
CORV

Clough Capital Partners’s Correvio Pharma Corp. Ordinary Shares (Canada) CORV Stock Holding History

Clough Capital Partners’s Portfolio CORV Stock Details CORV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2,057,124
Closed -$4.11M – 137
2019
Q3 		$4.11M Sell
2,057,124
-27,700
-1% -$56.1K 0.34% 56
2019
Q2 		$4.5M Sell
2,084,824
-26,400
-1% -$67.5K 0.44% 70
2019
Q1 		$6.67M Sell
2,111,224
-261,000
-11% -$844K 0.58% 62
2018
Q4 		$5.91M Buy
2,372,224
+232,930
+11% +$775K 0.69% 56
2018
Q3 		$8.6M Buy
2,139,294
+77,031
+4% +$340K 0.81% 45
2018
Q2 		$7.79M Sell
2,062,263
-13,400
-0.6% -$35K 0.7% 48
2018
Q1 		$4.82M Sell
2,075,663
-591,922
-22% -$936K 0.46% 62
2017
Q4 		$4.13M Sell
2,667,585
-211,400
-7% -$340K 0.34% 69
2017
Q3 		$6.13M Hold
2,878,985
– – 0.41% 63
2017
Q2 		$13M Sell
2,878,985
-79,430
-3% -$288K 0.9% 36
2017
Q1 		$8.9M Sell
2,958,415
-102,649
-3% -$303K 0.57% 55
2016
Q4 		$8.45M Hold
3,061,064
– – 0.56% 57
2016
Q3 		$9.58M Buy
3,061,064
+1,000,000
+49% +$3.65M 0.5% 70
2016
Q2 		$10.6M Buy
2,061,064
+16,411
+0.8% +$78.9K 0.56% 63
2016
Q1 		$8.36M Buy
2,044,653
+306,300
+18% +$1.64M 0.39% 77
2015
Q4 		$14.1M Buy
1,738,353
+154,270
+10% +$1.29M 0.66% 51
2015
Q3 		$13.4M Buy
1,584,083
+796,500
+101% +$7.34M 0.58% 59
2015
Q2 		$7.41M Buy
787,583
+190,400
+32% +$1.77M 0.28% 94
2015
Q1 		$5.53M Buy
597,183
+84,650
+17% +$811K 0.18% 128
2014
Q4 		$4.74M Buy
512,533
+13,529
+3% +$114K 0.17% 125
2014
Q3 		$4.46M Buy
499,004
+138,283
+38% +$1.01M 0.17% 120
2014
Q2 		$2.83M Buy
+360,721
New +$2.72M 0.09% 149

Other funds holding CORV

TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Clough Capital Partners's CORV Position: Q4 2019 in Review

Clough Capital Partners sold out of Correvio Pharma Corp. Ordinary Shares (Canada) (CORV) in Q4 2019, closing a stake of 2,057,124 shares — an estimated $4.11M sold.

Clough Capital Partners first reported a position in CORV in Q2 2014 and held it in 22 quarters. The position peaked at $14.1M in Q4 2015. 31 funds tracked by Wall St. Rank hold CORV as of Q4 2019.

  • Clough Capital Partners reported no remaining Correvio Pharma Corp. Ordinary Shares (Canada) position as of Q4 2019 after selling out during the quarter.
  • Clough Capital Partners sold 2,057,124 Correvio Pharma Corp. Ordinary Shares (Canada) shares in Q4 2019, an estimated $4.11M.
  • Clough Capital Partners first reported a position in Correvio Pharma Corp. Ordinary Shares (Canada) in Q2 2014 and held it in 22 quarters.
  • Clough Capital Partners's Correvio Pharma Corp. Ordinary Shares (Canada) position peaked at $14.1M in Q4 2015.
  • 31 funds tracked by Wall St. Rank held Correvio Pharma Corp. Ordinary Shares (Canada) as of Q4 2019.

Based on Clough Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.